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Purpose: This study was conducted to investigate and illustrate the use of Indium In- 111 
pentetreotide scintigraphy as it applies to carotid body tumors (CBT). Localization has 
relied primarily on ultrasonography, computed tomography, and magnetic resonance 
imaging with angiographic confirmation. These methods only assess the cervical bifurca- 
tion without providing an evaluation of metastasis n patients without symptoms or 
recurrence in patients after surgery. 
Methods: Indium In-111 pentetreotide scintigraphy was used in five patients with a 
diagnosis of CBT. Four patients were evaluated after surgical excision for evidence of 
tumor recurrence. One patient was evaluated before excision for diagnostic onfirmation. 
Results: No evidence of tumor recurrence was demonstrated in the four patients who had 
undergone previous CBT excision. One of these patients had increased activity in the 
pituitary, later confirmed as an enlarged pituitary without evidence of an adenoma with 
computed tomography. The diagnosis of CBT was confirmed in the patient evaluated 
before surgery. This patient also had increased activity in the occipital region, confirmed 
as the site of previous ischemia on computed tomography. 
Conclusion: Indium In-111 pentetreotide scintigraphy is a new innovative method for 
viewing neuroendocrine tumors. Its potential lies not only in tumor localization but also 
in identification of recurrent tumor at the operative site and metastatic disease. (J Vase 
Surg 1997;25:905-8.) 
Carotid body tumors are rare vascular tumors 
that arise from neural crest cell origin and are mem- 
bers of the amino precursors uptake and decarboxyl- 
ate system. 1 Although typically located at the carotid 
bifurcation, they can be found in sympathetic and 
parasympathetic tissue and are referred to as paragan- 
glionomas. Unique to these tumors and all neural 
endocrine tumors are their properties of  containing 
somatostatin receptor sites. It is this characteristic 
that has enabled localization studies based on recep- 
tor interaction to be performed. 
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Originally introduced in the Netherlands, In- 
dium In - l l l  pentetreotide scintigraphy allows for 
whole body images to detect umor location, multi- 
centricity, and metastasis n a relatively noninvasive 
fashion) This technique has primarily been applied 
to known secreting neuroendocrine tumors includ- 
ing insulinomas, pheochromocytomas, and carci- 
noids, but recently it was shown to have a high 
degree of  accuracy in localizing carotid body tumors. 
Kweld~eboom etal.1 report an accuracy of  94% when 
studying patients with multiple known paraganglio- 
mas. 
In an effort to better understand the application 
of this technology in localization and as a noninva- 
sive method for follow-up after the excision of ca- 
rotid body tumors, we evaluated five patients who 
had this diagnosis at our institution. 
METHODS 
Vascular ecords were reviewed from 1987 to the 
present o identify all patients who had a diagnosis of 
carotid body tumor. Four patients were identified as 
having undergone surgical excision, whereas a fifth 
patient presented with angiographic and computed 
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Table I. Summary of radiologic imaging 
and surgical resection in patients with 
angiographically confirmed carotid 
body tumors 
Radiologic Surgical 
Patient imaging resection 
Indium In-Hi 
pentetreotide 
imaging 
1 Left (CT, MRI) L 
2 Right (CT) R 
3 Right (CT) R 
4 Bilateral (MRI, CT) L 
5 Left (CT) None 
No recurrence 
No recurrence 
No recurrence 
No recurrence 
Localized 
MRI, Magnetic resonance imaging; R, right; L, left. 
Fig. 1. Magnetic resonance imaging depicts evidence of 
possible bilateral c rotid body tumors as indicated by ar- 
YOWS. 
tomographic (CT) confirmation that a carotid body 
tumor was present. All five patients underwent In- 
dium In - l l l  pentetreotide scintigraphy under an 
approved institutional protocol and informed con- 
sent. 
Indium In- 111 pentctreotide scintigraphy scans 
were performed with 6 mCi of Indium In- 111 pente- 
treotide administered intravenously. Indium In- 111 
pcntetreotide is constructed when Indium In-111 
reacts with the diethylenetriaminctctraacetic acid 
portion of the pentetreotidc molecule. 2 Anterior and 
posterior whole body images wcrc obtained with the 
Picker Prism 2000 (Picker International, Clcveland, 
Ohio) at 4, 24, and 48 hours after injection. The 
protocol includes a 40-minute acquisition on a 
128 × 256 matrix with the medium energy collima- 
tors and application of both the 171 keV and the 245 
keV pcaks with a 15% window. 
Single proton emission computed tomographic 
images of the head and neck, chest, abdomen, and 
pclvis were obtaincd on the Prism 2000 at 24 hours. 
The acquisition protocol includes a30-minute acqui- 
sition on a 64 × 64 matrix with the samc collimators 
and peaks as defined previously. A Butterworth filter 
(Picker International) with an order of 7.0 and a 
cutoff of 0.30 was used. 
Interpretation of the scans was independently 
performed by two nuclear medicine physicians who 
understood that the purpose was to evaluate for 
recurrence, metastasis, or localization of carotid 
body tumors. Images were displayed with color en- 
hancement of areas of uptake. Imaging was per- 
formed 24 hours after injection based on the assump- 
tion that normal uptake of Indium In - l l l  
pentetreotide would have been cleared and only ar- 
eas with somatostatin receptors would be seen at that 
time. The tumor was defined as being present or 
absent at the region of the carotid bifurcation. Ra- 
dioactivity outside of the neck region was likewise 
assessed. If any abnormal tracer was identified in 
other regions of the body, follow-up CT scans for the 
areas in question were obtained. Anatomic imaging 
methods were used after initial interpretations were 
made.  
RESULTS 
In all four patients who had undergone previous 
excision of a carotid body tumor, no evidence for 
recurrence or residual disease was seen (Table I). 
Patient four had a left neck mass and a magnetic 
resonance image that suggested bilateral neck tu- 
mors (Fig. 1). An angiographic scan was performed 
and demonstrated a carotid body tumor limited to 
the left neck. The patient underwent an uncompli- 
cated excision of a Shamblin type III carotid body 
tumor on the left side. 3 Indium In- 111 pentetreotide 
scintigraphy after surgery showed no residual tumor 
on the operative side and failed to demonstrate any 
tumor on the contralateral side, confirming the pre- 
operative angiographic studies. This patient did, 
however, show prominent uptake in the pituitary 
gland, which is an expected site of normal uptake 
(Fig. 2). 4 In patient four the pituitary gland was 
enlarged; thus uptake was increased and CT showed 
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Fig. 2. Arrow demonstrates prominent uptake in pituitary gland. No evidence for residual 
tumor on left, operative site. No tumor identified on right. 
no evidence of an adenoma. It is our supposition that 
the enlarged pituitary gland had a greater mass and a 
greater uptake of Indium In- 111 pentetreotide. Pa- 
tient five had a left neck mass seen on CT and 
angiography at the carotid bifurcation. Indium In- 
111 pentetreotide scintigraphy confirmed the tumor 
location, by definition identifying it as a carotid body 
tumor. Incidentally, activity was demonstrated in the 
occipital region, and a CT scan confirmed this to be a 
region of previous infarct (Fig. 3 ) .  
DISCUSSION 
Carotid body tumors are recognizably very rare 
vascular tumors. There appears to be two forms of 
the tumor type, a sporadic more-common form that 
carries approximately a 5% incidence of bilaterality 
and a familial form that is purported to have up to a 
33% incidence of bilaterality, s In addition to the 
potential for bilaterality, there have also been reports 
of metastasis occurring from 3% to 10%. s 7 In a 
retrospective r view of 55 patients over a 20-year 
period, Nora et al. 8 found a 2% incidence of metasta- 
sis and a 6% recurrence rate. This study did not 
perform total body imaging, and the one patient who 
died of  metastatic disease in this study had symptoms 
prompting identification. It ig unknown how many 
patients remain with asymptomatic metastasis. With 
the advent of Indium In- 111 pentetreotide scintigra-. 
phy, a method has become available that may help 
not only to localize the suspected neck tumor but: 
also to document the presence of metastatic disease' 
throughout the body in an accurate and noninvasive 
fashion. This technique for obtaining images pro- 
vides a noninvasive method for patient follow-up, 
enabling surgical intervention before the develop- 
ment of symptoms. Its accuracy remains promising 
but requires further investigation. 
The nuclear images are based on the tumor's 
properties of containing somatostatin receptors. Oc- 
treotide is a somatostatin analog that possesses many 
inhibitory actions. In the central nervous ystem so- 
matostatin functions as aneurotransmitter. As a hor- 
mone it has an inhibitory influence on a variety of 
hormones including growth hormone, insulin, glu- 
cagon, and gastrin. It is also known to have antipro- 
liferative ffects on tumors, angiogenesis, and modu- 
lation of immunologic actions. 4 Indeed, Indium In- 
111 pentetreotide was developed out of a need for a 
more stable carrier of radioisotopes that would 
mimic the action ofsomatostatin a d make scintigra- 
phy possible. 
The planar camera is generally sufficient to detect 
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low-up of  four patients who had undergone tumor 
excision. For patient four we postulate that the in- 
creased activity demonstrated in the pituitary gland 
may merely reflect the gland's enlargement, because 
an abnormality was not demonstrated on the CT 
scan. Further evaluation of  the baseline uptake of  the 
pituitary gland is required to determine the signifi- 
cance of  this finding. The significance of  the intrace- 
rebral tracer uptake in patient five, who had a previ- 
ous cerebral vascular accident seen on CT at this area, 
is unknown. 
Indium In- i 11 pentetreotide is a promising tech- 
nique that allows the noninvasive detection of  ca- 
rotid body tumors. It may also prove useful in deter- 
mining tumor recurrence, metastasis, and evaluation 
of  residual tumor after excision. In  selected patients 
this method of  investigation may prove useful for 
detection of  carotid body tumors before the onset o f  
symptoms, enabling excision at an earlier stage. 
Fig. 3. Full body Indium In-111 pentetreotide scintigra- 
phy. Large arrow demonstrates carotid body tumor local- 
ization to left neck. Small arrow shows minimal uptake in 
occipital region. 
concentrated isotope. With smaller tumors or in ar- 
eas o f  increased background activity, single proton 
emission CT scanning is more appropriate,  In our 
study single proton emission CT scanning was used 
to detect suspected tumor and to evaluate areas o f  
possible metastasis. 
Experience in localizing carotid body tumors 
with Indium In - l I1  pentetreotide scintigraphy is 
extremely limited. We were able to demonstrate clear 
localization in one patient who presented for initial 
treatment, and we found no residual disease on fol- 
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